1. A novel stable crystalline Gefitinib Form-6 having the characteristics given below:
XRPD: having typical characteristic peaks at about 7.05, 9.36, 12.3, 14.8, 16.8, 18.60,20.68, 24.72 on the 29 scale as shown in Fig 1 of the drawing accompanying this specification
DSC: having a typical first endotherm with a peak at approximately 66.4 to 82.4°C and a second endotherm with a peak at approximately 193.3 to 195.3°C as shown in Fig 2
K.F. value of 3.70%-3.95% w/w, preferably 3.75-3.85% w/w equivalent to monohydrate.
2. A process for the preparation of a novel crystalline form of Gefitinib, designated as Form-6 as
claimed in claim 1, which comprises mixing anhydrous Gefitinib of the formula-I,
I with water, stirring the resulting slurry at a temperature in the range of 25-30 °C for a period
ranging from 18 to about 20 hrs, filtering and air-drying the resultant Form-6 of Gefitinib
formed.
3. The process as claimed in claim 2 where in the stirring of anhydrous Gefitinib and the water
is effected for a period in the range of 15-25 hours, preferably between 18^20 hours.

1. A pharmaceutical composition comprising the novel stable crystalline Form-6 of Gefitinib as claimed in claim 1 and a pharmaceutically acceptable carrier.
>. A process for the preparation of a novel crystalline form of Gefitinib, designated as Form-6 laving the above mentioned characteristics, as claimed in claim 1 of Gefitinib of the formula-I ubstantially as herein described with reference to Example 1.